AI Article Synopsis
- The SLAM family, consisting of nine receptors on immune cells, is crucial in regulating immune responses in tumor environments and interacts significantly with cancer.
- Research indicates that SLAM can both enhance and suppress immune responses to tumors, affecting how cancers progress and respond to treatment.
- Advancements in technologies like single-cell RNA sequencing may allow for targeted therapies focusing on SLAM, paving the way for more personalized approaches to cancer treatment while emphasizing the need for patient safety and comprehensive clinical trials.
Article Abstract
In the field of oncology, the Signaling Lymphocyte Activation Molecule (SLAM) family is emerging as pivotal in modulating immune responses within tumor environments. The SLAM family comprises nine receptors, mainly found on immune cell surfaces. These receptors play complex roles in the interaction between cancer and the host immune system. Research suggests SLAM's role in both enhancing and dampening tumor-immune responses, influencing the progression and treatment outcomes of various cancers. As immunotherapy advances, resistance remains an issue. The nuanced roles of the SLAM family might provide answers. With the rise in technologies like single-cell RNA sequencing and advanced imaging, there is potential for precise SLAM-targeted treatments. This review stresses patient safety, the importance of thorough clinical trials, and the potential of SLAM-focused therapies to transform cancer care. In summary, SLAM's role in oncology signals a new direction for more tailored and adaptable cancer treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571764 | PMC |
| http://dx.doi.org/10.3390/cancers15194808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!